Camber Capital Management LP Ascendis Pharma A/S Transaction History
Camber Capital Management LP
- $2.67 Billion
- Q1 2025
A detailed history of Camber Capital Management LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Camber Capital Management LP holds 350,000 shares of ASND stock, worth $56.5 Million. This represents 2.05% of its overall portfolio holdings.
Number of Shares
350,000
Previous 800,000
56.25%
Holding current value
$56.5 Million
Previous $110 Million
50.47%
% of portfolio
2.05%
Previous 2.55%
Shares
10 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.66 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$885 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$843 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$725 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$688 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.02B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...